ORKA 001-113 Open Label Extension (OLE)
Brief description of study
This study is for adults with moderate-to-severe plaque psoriasis who have already participated in a previous Oruka Therapeutics study and choose to continue receiving ORKA-001 treatment. Participants may stay in the extension study for up to about 96 weeks and will then be followed for about 48 weeks after their last treatment visit.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: 99 years or below
-
Gender: All
TBD
Find a site
,
Send a message
Enter your contact details to connect with study team
Primary Contact
Interested in the study
Select a study center that’s convenient for you, and get in touch with the study team.
Contact a study centerPlease choose between Voice or SMS based delivery of verification code
or